Compare PMVP & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMVP | HNNA |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.1M | 79.2M |
| IPO Year | 2020 | 2005 |
| Metric | PMVP | HNNA |
|---|---|---|
| Price | $1.32 | $9.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 316.7K | 5.4K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.57% |
| EPS Growth | N/A | ★ 38.04 |
| EPS | N/A | ★ 0.73 |
| Revenue | N/A | ★ $54,590,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.59 |
| Revenue Growth | N/A | ★ 3.09 |
| 52 Week Low | $1.02 | $8.90 |
| 52 Week High | $1.88 | $13.00 |
| Indicator | PMVP | HNNA |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 48.00 |
| Support Level | $1.04 | $9.67 |
| Resistance Level | $1.33 | $10.29 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 77.50 | 26.23 |
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.